Literature DB >> 3013850

Processing of a newly identified intermediate of human myeloperoxidase in isolated granules occurs at neutral pH.

D T Akin, J M Kinkade.   

Abstract

Myeloperoxidase is a major component of specialized lysosomes known as azurophil granules in polymorphonuclear leukocytes or neutrophils. The processing of myeloperoxidase in human HL-60 promyelocytic leukemia cells was studied by pulse-labeling cells in culture with [35S]methionine followed by immunoprecipitation and identification of myeloperoxidase polypeptides from cell fractions after various chase intervals. These studies revealed the presence of a previously unidentified intermediate with Mr 74,000 which kinetically followed the appearance of a larger Mr 81,000 intermediate. Using an in vitro lysosomal preparation the newly identified Mr 74,000 intermediate was directly converted within protected granules to mature forms of myeloperoxidase (Mr 63,000 and 60,000). This conversion occurred optimally at pH 7.5 and was not inhibited by lysosomotropic agents (chloroquine, NH4Cl) or protonophores (monensin, carbonyl cyanide p-trifluoromethoxyphenylhydrazone). Furthermore, the uptake of radiolabeled amines indicated a neutral intragranular environment (pH 7.35-7.67) which remained unchanged in the presence and absence of 1 mM ATP or 2.5 microM carbonyl cyanide p-trifluoromethoxyphenylhydrazone. We conclude that, in contrast to other lysosomal pathways, the final proteolytic cleavage of myeloperoxidase does not require an acidic environment.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3013850

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  The early and late processing of lysosomal enzymes: proteolysis and compartmentation.

Authors:  A Hasilik
Journal:  Experientia       Date:  1992-02-15

Review 2.  Biosynthesis of human myeloperoxidase.

Authors:  William M Nauseef
Journal:  Arch Biochem Biophys       Date:  2018-02-03       Impact factor: 4.013

3.  Immunological detection of myeloperoxidase in synovial fluid from patients with rheumatoid arthritis.

Authors:  S W Edwards; V Hughes; J Barlow; R Bucknall
Journal:  Biochem J       Date:  1988-02-15       Impact factor: 3.857

4.  Monensin disruption of neutrophil granule genesis.

Authors:  R T Parmley; J M Kinkade; D T Akin; C S Gilbert; G S Guzman
Journal:  Am J Pathol       Date:  1988-12       Impact factor: 4.307

Review 5.  Lactoperoxidase: structural insights into the function,ligand binding and inhibition.

Authors:  Sujata Sharma; Amit Kumar Singh; Sanket Kaushik; Mau Sinha; Rashmi Prabha Singh; Pradeep Sharma; Harshverdhan Sirohi; Punit Kaur; Tej P Singh
Journal:  Int J Biochem Mol Biol       Date:  2013-09-13

6.  Proconvertase proteolytic processing of an enzymatically active myeloperoxidase precursor.

Authors:  Sally McCormick; Angela Nelson; William M Nauseef
Journal:  Arch Biochem Biophys       Date:  2012-08-10       Impact factor: 4.013

7.  Distinctive inhibition of the lysosomal targeting of lysozyme and cathepsin D by drugs affecting pH gradients and protein kinase C.

Authors:  J Radons; U Biewusch; S Grässel; H J Geuze; A Hasilik
Journal:  Biochem J       Date:  1994-09-01       Impact factor: 3.857

8.  T47D Cells Expressing Myeloperoxidase Are Able to Process, Traffic and Store the Mature Protein in Lysosomes: Studies in T47D Cells Reveal a Role for Cys319 in MPO Biosynthesis that Precedes Its Known Role in Inter-Molecular Disulfide Bond Formation.

Authors:  Richard P Laura; David Dong; Wanda F Reynolds; Richard A Maki
Journal:  PLoS One       Date:  2016-02-18       Impact factor: 3.240

9.  Structure of human promyeloperoxidase (proMPO) and the role of the propeptide in processing and maturation.

Authors:  Irina Grishkovskaya; Martina Paumann-Page; Rupert Tscheliessnig; Johanna Stampler; Stefan Hofbauer; Monika Soudi; Benjamin Sevcnikar; Chris Oostenbrink; Paul G Furtmüller; Kristina Djinović-Carugo; William M Nauseef; Christian Obinger
Journal:  J Biol Chem       Date:  2017-03-27       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.